Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Cholestasis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 019821 Part 01, page:10 PDF 7773k",https://www.pharmapendium.com/browse/fda/Acitretin/1a0cb7a639fe6c5d73334f9d95bc1bc6?reference=10,1996.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Amoxicillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O,Cholestasis,Human,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050542/S-017; 050754/S-002; 050760/S-001; 050761/S-001, page:4 PDF 275k",https://www.pharmapendium.com/browse/fda/Amoxicillin/079f6473e812ed6a6222837d00e49d6e?reference=4,1999.0,CC1(C)S[CH]2[CH](NC(=O)[CH](N)C3=CC=C(O)C=C3)C(=O)N2[CH]1C(O)=O
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Cholestasis,Human,-0.6989700043360189,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/304231/2020; EMEA/H/C/000788/II/0040, page:61 PDF 3676k",https://www.pharmapendium.com/browse/ema/Anidulafungin/5a5991756b23170ddf3bf5cbcf6a6d04?reference=61,2020.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Atorvastatin Calcium,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,Cholestasis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Printed Labeling 077575/S-000, page:26 PDF 8877k",https://www.pharmapendium.com/browse/fda/Atorvastatin Calcium/b2b778f4f7c1d7393c50ff220ea5034f?reference=26,2010.0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[CH](O)C[CH](O)CC([O-])=O)C1=CC=C(F)C=C1
Brigatinib,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2P(C)(C)=O)=C(Cl)C=N1)N1CCC(CC1)N1CCN(C)CC1,Cholestasis,Human,-2.255272505103306,Repeated,Oral,"EMA approval document: Assessment Report EMA/140650/2020; EMEA/H/C/004248/II/0003, page:79 PDF 5666k",https://www.pharmapendium.com/browse/ema/Brigatinib/90bc8094fb1cd300b7ee28bf690bb302?reference=79,2020.0,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2P(C)(C)=O)=C(Cl)C=N1)N1CCC(CC1)N1CCN(C)CC1
Cefadroxil,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,Cholestasis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 050527/S-009, page:29 PDF 2946k",https://www.pharmapendium.com/browse/fda/Cefadroxil/8f1f4d9eb86135ccadf08e3cb7095dbf?reference=29,1991.0,[H][C]12SCC(C)=C(N1C(=O)[CH]2NC(=O)[CH](N)C1=CC=C(O)C=C1)C(O)=O
Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,Cholestasis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Printed Labeling 050749/S-000, page:23 PDF 1493k",https://www.pharmapendium.com/browse/fda/Cefdinir/10c4f05e362d284ea2ef7800cb8bc9b3?reference=23,1997.0,[H][C]12SCC(C=C)=C(N1C(=O)[CH]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
Cefmenoxime Hydrochloride,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1,Cholestasis,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050571 Part 01, page:10 PDF 5151k",https://www.pharmapendium.com/browse/fda/Cefmenoxime Hydrochloride/d2aca4fcb286f5a4bc51c0e42c7c6d63?reference=10,1987.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1
Cefpodoxime Proxetil,COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N\OC)\C1=CSC(N)=N1)C2=O)C(=O)OC(C)OC(=O)OC(C)C,Cholestasis,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 050687 Part 01, page:23 PDF 4381k",https://www.pharmapendium.com/browse/fda/Cefpodoxime Proxetil/5ffa088364de86a8a3c0e1d525cdef88?reference=23,1992.0,COCC1=C(N2[CH](SC1)[CH](NC(=O)C(=N\OC)\C1=CSC(N)=N1)C2=O)C(=O)OC(C)OC(=O)OC(C)C
Ceftazidime,[H][C@]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O,Cholestasis,Human,-3.4771212547196626,Repeated,Parenteral,"FDA approval package document: Approval Package 050646 Part 01, page:28 PDF 5617k",https://www.pharmapendium.com/browse/fda/Ceftazidime/04d84e2f3ec0d275868d36da01f7904e?reference=28,1991.0,[H][C]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[CH]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O
Ceftriaxone Sodium,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(O)=NN3C)=C(N2C1=O)C([O-])=O)/C1=CSC(N)=N1,Cholestasis,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050585 Part 06, page:24 PDF 7328k",https://www.pharmapendium.com/browse/fda/Ceftriaxone Sodium/12c252b83bc92a9fc2555e0e278fb2b2?reference=24,1984.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(CSC3=NC(=O)C(O)=NN3C)=C(N2C1=O)C([O-])=O)/C1=CSC(N)=N1
Cefuroxime Axetil,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)\C1=CC=CO1,Cholestasis,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 050605 Part 09, page:77 PDF 5645k",https://www.pharmapendium.com/browse/fda/Cefuroxime Axetil/d6ec5b3db48f2d5405a5e3835b2265a1?reference=77,1985.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)\C1=CC=CO1
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Cholestasis,Human,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/386332/2017; EMEA/H/C/003819/II/0012, page:71 PDF 6439k",https://www.pharmapendium.com/browse/ema/Ceritinib/0ce99201261a9d8e84a0cbcfc52ed714?reference=71,2017.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Cetirizine Hydrochloride,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Cholestasis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 211415 Part 02, page:23 PDF 633k",https://www.pharmapendium.com/browse/fda/Cetirizine Hydrochloride/8dde7db6745268cda600303e6898c430?reference=23,2019.0,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Cholic acid,[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])C[C@H](O)[C@]3(C)[C@]([H])(CC[C@@]3([H])[C@]1([H])[C@H](O)C2)[C@H](C)CCC(O)=O,Cholestasis,Human,-1.1760912590556813,Repeated,Oral,"EMA approval document: Assessment Report EMA/689761/2015; EMEA/H/C/002081/0000, page:80 PDF 2581k",https://www.pharmapendium.com/browse/ema/Cholic acid/16f0969d53af4cf8b70716b378a4f9d6?reference=80,2015.0,[H][C]12C[CH](O)CC[C]1(C)[C]1([H])C[CH](O)[C]3(C)[C]([H])(CC[C]3([H])[C]1([H])[CH](O)C2)[CH](C)CCC(O)=O
Cimetidine,CN\C(NC#N)=N/CCSCC1=C(C)NC=N1,Cholestasis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 020238 Part 03, page:88 PDF 7977k",https://www.pharmapendium.com/browse/fda/Cimetidine/34f280f054a5a4e91c78bf34d1aa8f5b?reference=88,1995.0,CN\C(NC#N)=N/CCSCC1=C(C)NC=N1
Clopidogrel Hydrochloride,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl,Cholestasis,Human,-1.8750612633917,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Clopidogrel Besilate394.full   ---   DOI:10.7326/0003-4819-129-5-199809010-00009   JOURNAL:Annals of Internal Medicine   PAGES:394   VOLUME:129,http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00009,1998.0,COC(=O)[CH](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl
Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,Cholestasis,Human,-2.6532125137753435,Repeated,Oral,"FDA approval package document: Review 019758/S-047, page:33 PDF 10755k",https://www.pharmapendium.com/browse/fda/Clozapine/074375bc33fa11cc8237082bf942999f?reference=33,2002.0,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2
Cobicistat,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,Cholestasis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203094/S-000 Part 05, page:74 PDF 15871k",https://www.pharmapendium.com/browse/fda/Cobicistat/cf97ec370dc39aa6baa9336ae252e4c6?reference=74,2012.0,CC(C)C1=NC(CN(C)C(=O)N[CH](CCN2CCOCC2)C(=O)N[CH](CC[CH](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
Conivaptan Hydrochloride,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,Cholestasis,Human,-1.9030899869919435,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 021697/S-000 Part 03, page:67 PDF 4991k",https://www.pharmapendium.com/browse/fda/Conivaptan Hydrochloride/011e8a458cc05207fd7bccbe97a4a265?reference=67,2005.0,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1
Cyclobenzaprine Hydrochloride,CN(C)CC\C=C1\C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Cholestasis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021777/S-000, page:21 PDF 6375k",https://www.pharmapendium.com/browse/fda/Cyclobenzaprine Hydrochloride/d2cb881e69752f874659302be787c471?reference=21,2005.0,CN(C)CC\C=C1\C2=C(C=CC=C2)C=CC2=C1C=CC=C2
Cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,Cholestasis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 203856/S-000, page:7 PDF 333k",https://www.pharmapendium.com/browse/fda/Cyclophosphamide/d134b6b0c0f1d60144f6d82dbd25f9e9?reference=7,2013.0,ClCCN(CCCl)P1(=O)NCCCO1
Dasatinib,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1,Cholestasis,Human,-2.146128035678238,Repeated,Oral,"FDA approval package document: Approval Package 021986/S-001, S-002 Part 01, page:24 PDF 1825k",https://www.pharmapendium.com/browse/fda/Dasatinib/3d6b547558ea3de73b9adee20b77c38a?reference=24,2007.0,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1
Desloratadine,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1,Cholestasis,Human,-0.6989700043360189,Repeated,Oral,Reference from PharmaPendium Published Toxicity: desloratadine_3647   ---   DOI:10.3748/wjg.v11.i23.3647   JOURNAL:World Journal of Gastroenterology   PAGES:3647   VOLUME:11,http://dx.doi.org/10.3748/wjg.v11.i23.3647,2005.0,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1
Diazepam,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C12,Cholestasis,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 013263/S-003, S-008, S-019, S-040, S-041, S-042, S-043, S-046, S-049, S-054; 016087/S-040, S-042, S-045; 017984/S-010; 018179/S-001 Part 01, page:23 PDF 4467k",https://www.pharmapendium.com/browse/fda/Diazepam/c07af973f7b6af41e0a0b1e6c18fe979?reference=23,1963.0,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C12
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Cholestasis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 204629/S-001, S-002, S-003 Part 02, page:20 PDF 4874k",https://www.pharmapendium.com/browse/fda/Empagliflozin/d9389650199146fc07985b7833daf787?reference=20,2015.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,Cholestasis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019834/S-001, S-002, S-009 Part 12, page:4 PDF 8679k",https://www.pharmapendium.com/browse/fda/Felodipine/616fdcf13eea5049c9b29b37b2a513f4?reference=4,1997.0,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Cholestasis,Human,-2.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 01, page:20 PDF 743k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/7282c9edf57b7af5577d3d55b966b526?reference=20,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Flucloxacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O,Cholestasis,Human,-4.653212513775344,Repeated,Unreported,Reference from PharmaPendium Published Toxicity: Flucloxacillin-0076   ---   DOI:10.1111/j.1365-2125.2005.02370.x   JOURNAL:British Journal of Clinical Pharmacology   PAGES:76   VOLUME:60,http://dx.doi.org/10.1111/j.1365-2125.2005.02370.x,2005.0,[H][C]12SC(C)(C)[CH](N1C(=O)[CH]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O
Ganciclovir,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,Cholestasis,Human,-1.0,Repeated,Intravenous,"FDA approval package document: Approval Package 020460/S-005 Part 01, page:40 PDF 5337k",https://www.pharmapendium.com/browse/fda/Ganciclovir/af8b89aafda27afd4ca3e4f3b3ba71ff?reference=40,1994.0,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
Ganciclovir Sodium,NC1=NC2=C(N=CN2COC(CO)CO)C([O-])=N1,Cholestasis,Human,-3.4771212547196626,Repeated,Oral,"FDA approval package document: Label 019661/S-030, page:20 PDF 690k",https://www.pharmapendium.com/browse/fda/Ganciclovir Sodium/0078e0911648eae74c95fa905199c725?reference=20,2006.0,NC1=NC2=C(N=CN2COC(CO)CO)C([O-])=N1
Glimepiride,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,Cholestasis,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Label 020496/S-015, page:10 PDF 279k",https://www.pharmapendium.com/browse/fda/Glimepiride/78c66922e53dc9a8e6ff87e31f73c73f?reference=10,2005.0,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[CH]2CC[CH](C)CC2)C1=O
Ibrutinib,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,Cholestasis,Human,-2.6232492903979003,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/473724/2015; EMEA/H/C/003791/II/0001, page:40 PDF 2703k",https://www.pharmapendium.com/browse/ema/Ibrutinib/3509c053a50f597a98dadfa00620acfc?reference=40,2015.0,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[CH]1CCCN(C1)C(=O)C=C
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Cholestasis,Human,-2.6020599913279625,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020966, page:10 PDF 2870k",https://www.pharmapendium.com/browse/fda/Itraconazole/e816200206ea1ca7ddfdaba8985ae24d?reference=10,1998.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Labetalol Hydrochloride,CC(CCC1=CC=CC=C1)NCC(O)C1=CC=C(O)C(=C1)C(N)=O,Cholestasis,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 018687/S-002, S-005, S-008; 018686/S-005, S-006 Part 07, page:5 PDF 1143k",https://www.pharmapendium.com/browse/fda/Labetalol Hydrochloride/1d66471c2f8636c04d66cea9d2ff1557?reference=5,1989.0,CC(CCC1=CC=CC=C1)NCC(O)C1=CC=C(O)C(=C1)C(N)=O
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,Cholestasis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020406 Part 03, page:57 PDF 4102k",https://www.pharmapendium.com/browse/fda/Lansoprazole/09618525313fa9c4e0aeb7c47359985f?reference=57,1995.0,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Cholestasis,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:12 PDF 479k",https://www.pharmapendium.com/browse/ema/Leflunomide/143ff05cfedd6e28c7e1a3db69e310f5?reference=12,2018.0,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Cholestasis,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:40 PDF 659k",https://www.pharmapendium.com/browse/ema/Lenalidomide/085a38d0a6c5475c2831f18710affde9?reference=40,2020.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Levocetirizine Dihydrochloride,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Cholestasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022064/S-000 Part 02, page:11 PDF 6317k",https://www.pharmapendium.com/browse/fda/Levocetirizine Dihydrochloride/6e77c5fb26d411d9f53632e63bde15a2?reference=11,2007.0,OC(=O)COCCN1CCN(CC1)[CH](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Linagliptin,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,Cholestasis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201280/S-000 Part 04, page:98 PDF 5485k",https://www.pharmapendium.com/browse/fda/Linagliptin/4040600348d5f8e24c3f5c858638a448?reference=98,2010.0,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[CH](N)C1
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Cholestasis,Human,-0.9030899869919435,Repeated,Subcutaneous,"FDA approval package document: Approval Package 022341/S-027 Part 19, page:14 PDF 1904k",https://www.pharmapendium.com/browse/fda/Liraglutide/45c372c948e76993f3ca08708a92b5ea?reference=14,2016.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Cholestasis,Human,-1.0413926851582251,Repeated,Intravenous,"FDA approval package document: Approval Package 021506/S-023 Part 04, page:18 PDF 843k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/dca39f0e0ffa249fabd42e4f2e600cd3?reference=18,2019.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC,Cholestasis,Human,-1.954242509439325,Repeated,Oral,"FDA approval package document: Approval Package 077410/S-000 Part 01, page:18 PDF 8529k",https://www.pharmapendium.com/browse/fda/Nifedipine/fd1fd8c55b113ef9c9793784895e6f15?reference=18,2007.0,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Cholestasis,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: ANNEX I, page:17 PDF 1383k",https://www.pharmapendium.com/browse/ema/Nilotinib Hydrochloride Monohydrate/f1f0d28ac04823330e8921a3f480f0ab?reference=17,2021.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Cholestasis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207999/S-000 Part 04, page:69 PDF 18785k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/fd9575acfa8e5dadbfa0aa39e5adfd26?reference=69,2016.0,[H][C]1(CC[C]2([H])[C]3([H])[CH](O)[CH](CC)[C]4([H])C[CH](O)CC[C]4(C)[C]3([H])CC[C]12C)[CH](C)CCC(O)=O
Ofloxacin,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Cholestasis,Human,-0.6020599913279624,Repeated,Ocular,"FDA approval package document: Approval Package 019921/S-002, S-003 Part 02, page:53 PDF 6725k",https://www.pharmapendium.com/browse/fda/Ofloxacin/06e91db65808d9b5cfe279299ecb0a18?reference=53,1993.0,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Cholestasis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 362k",https://www.pharmapendium.com/browse/ema/Olanzapine/0b984055cecd3479ce4757f6aea84b40?reference=5,2021.0,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Cholestasis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019810/S-002, S-007, S-036, S-037, S-009, S-010, S-022, S-035, S-019, S-023, S-025, S-033, S-034; 050662/S-010 Part 21, page:45 PDF 6127k",https://www.pharmapendium.com/browse/fda/Omeprazole/1f18354d13e32eec8cbbb691e34fed35?reference=45,1990.0,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Omeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Cholestasis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Label 022056/S-000, page:11 PDF 2266k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/c3fb9402da19707d4ab213bad3649554?reference=11,,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Oxycodone Hydrochloride,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@H](C4)[C@]1(O)CCC2=O,Cholestasis,Human,-2.806179973983887,Repeated,Oral,"FDA approval package document: Label 022272/S-014 Part 01, page:14 PDF 347k",https://www.pharmapendium.com/browse/fda/Oxycodone Hydrochloride/b57612a4c34720a330e30805107a6275?reference=14,2013.0,[H][C]12OC3=C(OC)C=CC4=C3[C]11CCN(C)[CH](C4)[C]1(O)CCC2=O
Pantoprazole Sodium,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,Cholestasis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020987/S-007, page:36 PDF 1373k",https://www.pharmapendium.com/browse/fda/Pantoprazole Sodium/fc792609ea1639d725d409fa83f0f250?reference=36,2002.0,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1
Penicillamine,CC(C)(S)[C@H](N)C(O)=O,Cholestasis,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 019853/S-012 Part 02, page:8 PDF 3211k",https://www.pharmapendium.com/browse/fda/Penicillamine/bcf233dfb3d503a17a4ca97834344678?reference=8,2004.0,CC(C)(S)[CH](N)C(O)=O
Pexidartinib Hydrochloride,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,Cholestasis,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 211810/S-000 Part 07, page:42 PDF 855k",https://www.pharmapendium.com/browse/fda/Pexidartinib Hydrochloride/b8014b9a95e2f8615062ebf1f04be996?reference=42,2019.0,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Cholestasis,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: ANNEX I, page:10 PDF 591k",https://www.pharmapendium.com/browse/ema/Posaconazole/0cf742aa433cd6743730c864be18924d?reference=10,2016.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Proguanil Hydrochloride,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,Cholestasis,Human,-0.7781512503836436,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Ann. Pharmacother.; VOL 32 ISS Oct 1998, P1023-1025, (REF 9)   ---   JOURNAL:Annals of Pharmacotherpy   PAGES:1023   VOLUME:32",,1998.0,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Cholestasis,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Approval Package 203085/S-007 Part 02, page:13 PDF 4415k",https://www.pharmapendium.com/browse/fda/Regorafenib/026d8fc72a2854bedeae72aaf2cf5906?reference=13,2016.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,Cholestasis,Human,-2.0,Repeated,Intravenous,"EMA approval document: Public Assessment Report, page:150 PDF 5413k",https://www.pharmapendium.com/browse/ema/Remdesivir/29484e8f593af0a4f0b7e224d45ebbd2?reference=150,2020.0,CCC(CC)COC(=O)[CH](C)N[P](=O)(OC[CH]1O[C](C#N)([CH](O)[CH]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1
Riluzole,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1,Cholestasis,Human,-2.0,Repeated,Oral,"EMA approval document: Scientific Discussion, page:11 PDF 129k",https://www.pharmapendium.com/browse/ema/Riluzole/2fdd9339a096dccfb4bff884eb25d66e?reference=11,2004.0,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Cholestasis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 02, page:4 PDF 2110k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/89baeace45e27c62f8f6a207f9355b2d?reference=4,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rufinamide,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,Cholestasis,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Assessment Report EMA/491276/2018; EMEA/H/C/000660/II/0045, page:83 PDF 4033k",https://www.pharmapendium.com/browse/ema/Rufinamide/fc098c16b2c5858fc04c72f24aac15a8?reference=83,2018.0,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1
Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,Cholestasis,Human,-3.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020828/S-000 Part 02, page:18 PDF 2254k",https://www.pharmapendium.com/browse/fda/Saquinavir/4045cc38d98ff9cbac7aa47b8703ba3b?reference=18,1997.0,[H][C]12CCCC[C]1([H])CN(C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)[CH](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[CH](C2)C(=O)NC(C)(C)C
Stanozolol,[H][C@@]12CC[C@]3([H])[C@]([H])(CC[C@@]4(C)[C@@]3([H])CC[C@]4(C)O)[C@@]1(C)CC1=C(C2)NN=C1,Cholestasis,Human,-1.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Stanozolol-0026b   ---   JOURNAL:British Medical Journal   PAGES:612   VOLUME:294,,1987.0,[H][C]12CC[C]3([H])[C]([H])(CC[C]4(C)[C]3([H])CC[C]4(C)O)[C]1(C)CC1=C(C2)NN=C1
Stiripentol,CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1,Cholestasis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206709/S-000; 207223/S-000 Part 01, page:173 PDF 2233k",https://www.pharmapendium.com/browse/fda/Stiripentol/2fa86c5ab0867c548d9f0e4245ea5508?reference=173,2018.0,CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Cholestasis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 14, page:43 PDF 9336k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/5ca35442c7a6262bcfb861e4be5ed2ab?reference=43,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Cholestasis,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: ANNEX I, page:13 PDF 363k",https://www.pharmapendium.com/browse/ema/Tacrolimus/ddd3b1dc3f5b88ac9eef8ad12572c596?reference=13,2020.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Cholestasis,Human,-0.8450980400142568,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:79 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=79,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Ticlopidine Hydrochloride,ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2,Cholestasis,Human,-2.3979400086720375,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Clopidogrel Besilate394.full   ---   DOI:10.7326/0003-4819-129-5-199809010-00009   JOURNAL:Annals of Internal Medicine   PAGES:394   VOLUME:129,http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00009,1998.0,ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
Tigecycline,[H][C@@]12CC3=C(C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C,Cholestasis,Human,-2.0,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 211158/S-000, page:7 PDF 1264k",https://www.pharmapendium.com/browse/fda/Tigecycline/bb84822634f11b4b9e106fa84d0dbfd5?reference=7,2018.0,[H][C]12CC3=C(C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C
Tizanidine Hydrochloride,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,Cholestasis,Human,-1.5563025007672873,Repeated,Oral,"FDA approval package document: Medical Officer Review 020397, page:6 PDF 728k",https://www.pharmapendium.com/browse/fda/Tizanidine Hydrochloride/fadd8cf1a4115fd6ce090d88629487af?reference=6,1994.0,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
Trazodone Hydrochloride,ClC1=CC(=CC=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,Cholestasis,Human,-2.574031267727719,Repeated,Oral,"FDA approval package document: Label 022411/S-000, page:11 PDF 1121k",https://www.pharmapendium.com/browse/fda/Trazodone Hydrochloride/a511d30aeae8c87a776cb787b11bb761?reference=11,2010.0,ClC1=CC(=CC=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
Triazolam,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12,Cholestasis,Human,-1.3979400086720377,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Triazolam-0057   ---   DOI:10.1136/pgmj.57.673.730   JOURNAL:Postgraduate Medical Journal   PAGES:730   VOLUME:57,http://dx.doi.org/10.1136/pgmj.57.673.730,1981.0,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12
Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,Cholestasis,Human,-2.9822712330395684,Repeated,Oral,"EMA approval document: Assessment Report EMA/200986/2012; EMEA/H/C/002409, page:78 PDF 1852k",https://www.pharmapendium.com/browse/ema/Vemurafenib/3f4e6b934f558fc729afc31971243828?reference=78,2011.0,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Vigabatrin,NC(CCC(O)=O)C=C,Cholestasis,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Label 020427/S-000, page:15 PDF 2454k",https://www.pharmapendium.com/browse/fda/Vigabatrin/fb7a2d2ef7a099dfe4730b88a5a91ea4?reference=15,2009.0,NC(CCC(O)=O)C=C
Vismodegib,CS(=O)(=O)C1=CC=C(C(=O)NC2=CC=C(Cl)C(=C2)C2=CC=CC=N2)C(Cl)=C1,Cholestasis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203388/S-000 Part 05, page:2 PDF 3891k",https://www.pharmapendium.com/browse/fda/Vismodegib/bd7fd457ff1c4214c257ac8307d96b83?reference=2,2012.0,CS(=O)(=O)C1=CC=C(C(=O)NC2=CC=C(Cl)C(=C2)C2=CC=CC=N2)C(Cl)=C1
Voglibose,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,Cholestasis,Human,-1.591064607026499,Repeated,Unreported,Reference from PharmaPendium Published Toxicity: Voglibose09   ---   DOI:10.2169/internalmedicine.40.484   JOURNAL:Internal Medicine   PAGES:484   VOLUME:40,http://dx.doi.org/10.2169/internalmedicine.40.484,2001.0,OCC(CO)N[CH]1C[C](O)(CO)[CH](O)[CH](O)[CH]1O
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Cholestasis,Human,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Approval Package 021266/S-009, 021267/S-009, 021630/S-003 Part 03, page:5 PDF 309k",https://www.pharmapendium.com/browse/fda/Voriconazole/6bf2dd491c6903c4f6aa215436a65f75?reference=5,2004.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
